{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:44:14Z","timestamp":1794491054669,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG062713"],"award-info":[{"award-number":["R01AG062713"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K24AG073527"],"award-info":[{"award-number":["K24AG073527"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K23HL151903"],"award-info":[{"award-number":["K23HL151903"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40266-024-01142-9","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T08:28:43Z","timestamp":1726043323000},"page":"763-773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prospective Monitoring of New Drugs in Older Adults with and without Frailty: Near-Real-Time Assessment of Effectiveness and Safety of Oral Anticoagulants in Medicare Data"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1174-7535","authenticated-orcid":false,"given":"Darae","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kueiyu Joshua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Been","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Glynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7290-6838","authenticated-orcid":false,"given":"Dae Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"1142_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101652","volume":"79","author":"M Proietti","year":"2022","unstructured":"Proietti M, Romiti GF, Raparelli V, et al. Frailty prevalence and impact on outcomes in patients with atrial fibrillation: a systematic review and meta-analysis of 1,187,000 patients. Ageing Res Rev. 2022;79: 101652. https:\/\/doi.org\/10.1016\/j.arr.2022.101652.","journal-title":"Ageing Res Rev"},{"key":"1142_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.42964","volume":"5","author":"D Ko","year":"2022","unstructured":"Ko D, Lin KJ, Bessette LG, et al. Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010\u20132020. JAMA Netw Open. 2022;5: e2242964. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.42964.","journal-title":"JAMA Netw Open"},{"key":"1142_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.120.017024","volume":"9","author":"F Dalgaard","year":"2020","unstructured":"Dalgaard F, Xu H, Matsouaka RA, et al. Management of atrial fibrillation in older patients by morbidity burden: insights from get with the guidelines-atrial fibrillation. J Am Heart Assoc. 2020;9: e017024. https:\/\/doi.org\/10.1161\/jaha.120.017024.","journal-title":"J Am Heart Assoc"},{"key":"1142_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12916-020-01870-w","volume":"18","author":"C Wilkinson","year":"2020","unstructured":"Wilkinson C, Wu J, Searle SD, et al. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial. BMC Med. 2020;18:401. https:\/\/doi.org\/10.1186\/s12916-020-01870-w.","journal-title":"BMC Med"},{"issue":"9","key":"1142_CR5","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.7326\/m20-7141","volume":"174","author":"DH Kim","year":"2021","unstructured":"Kim DH, Pawar A, Gagne JJ, et al. Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation: a cohort study. Ann Intern Med. 2021;174(9):1214\u201323. https:\/\/doi.org\/10.7326\/m20-7141.","journal-title":"Ann Intern Med"},{"key":"1142_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039.","journal-title":"N Engl J Med"},{"key":"1142_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638.","journal-title":"N Engl J Med"},{"key":"1142_CR8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med"},{"key":"1142_CR9","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/gerona\/glx229","volume":"73","author":"DH Kim","year":"2018","unstructured":"Kim DH, Schneeweiss S, Glynn RJ, et al. Measuring frailty in medicare data: development and validation of a claims-based frailty index. J Gerontol A Biol Sci Med Sci. 2018;73:980\u20137. https:\/\/doi.org\/10.1093\/gerona\/glx229.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1142_CR10","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/gerona\/glz224","volume":"75","author":"DH Kim","year":"2020","unstructured":"Kim DH, Patorno E, Pawar A, et al. Measuring frailty in administrative claims data: comparative performance of four claims-based frailty measures in the U.S. Medicare Data. J Gerontol A Biol Sci Med Sci. 2020;75:1120\u20135. https:\/\/doi.org\/10.1093\/gerona\/glz224.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1142_CR11","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/gerona\/glaa150","volume":"76","author":"N Gautam","year":"2021","unstructured":"Gautam N, Bessette L, Pawar A, Levin R, Kim DH. Updating international classification of diseases 9th revision to 10th revision of a claims-based frailty index. J Gerontol A Biol Sci Med Sci. 2021;76:1316\u20137. https:\/\/doi.org\/10.1093\/gerona\/glaa150.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1142_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/clpt.2011.369","volume":"92","author":"JJ Gagne","year":"2012","unstructured":"Gagne JJ, Glynn RJ, Rassen JA, et al. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin Pharmacol Ther. 2012;92:80\u20136. https:\/\/doi.org\/10.1038\/clpt.2011.369.","journal-title":"Clin Pharmacol Ther"},{"key":"1142_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/pds.3616","volume":"23","author":"JJ Gagne","year":"2014","unstructured":"Gagne JJ, Wang SV, Rassen JA, Schneeweiss S. A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. Pharmacoepidemiol Drug Saf. 2014;23:619\u201327. https:\/\/doi.org\/10.1002\/pds.3616.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1142_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s40264-014-0136-0","volume":"37","author":"JJ Gagne","year":"2014","unstructured":"Gagne JJ, Rassen JA, Choudhry NK, et al. Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. Drug Saf. 2014;37:151\u201361. https:\/\/doi.org\/10.1007\/s40264-014-0136-0.","journal-title":"Drug Saf"},{"key":"1142_CR15","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jval.2015.08.011","volume":"18","author":"JJ Gagne","year":"2015","unstructured":"Gagne JJ, Bykov K, Najafzadeh M, et al. Prospective benefit-risk monitoring of new drugs for rapid assessment of net favorability in electronic health care data. Value Health. 2015;18:1063\u20139. https:\/\/doi.org\/10.1016\/j.jval.2015.08.011.","journal-title":"Value Health."},{"key":"1142_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12877-020-01739-w","volume":"20","author":"N Festa","year":"2020","unstructured":"Festa N, Shi SM, Kim DH. Accuracy of diagnosis and health service codes in identifying frailty in Medicare data. BMC Geriatr. 2020;20:329. https:\/\/doi.org\/10.1186\/s12877-020-01739-w.","journal-title":"BMC Geriatr"},{"key":"1142_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/gerona\/gly197","volume":"74","author":"DH Kim","year":"2019","unstructured":"Kim DH, Glynn RJ, Avorn J, et al. Validation of a claims-based frailty index against physical performance and adverse health outcomes in the health and retirement study. J Gerontol A Biol Sci Med Sci. 2019;74:1271\u20136. https:\/\/doi.org\/10.1093\/gerona\/gly197.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1142_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glae094","author":"SDM Sison","year":"2024","unstructured":"Sison SDM, Shi SM, Oh G, et al. Claims-based frailty index and its relationship with commonly used clinical frailty measures. J Gerontol A Biol Sci Med Sci. 2024. https:\/\/doi.org\/10.1093\/gerona\/glae094.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1142_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245\u201351. https:\/\/doi.org\/10.1016\/0895-4356(94)90129-5.","journal-title":"J Clin Epidemiol"},{"key":"1142_CR20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/01.mlr.0000160417.39497.a9","volume":"43","author":"E Birman-Deych","year":"2005","unstructured":"Birman-Deych E, Waterman AD, Yan Y, et al. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care. 2005;43:480\u20135. https:\/\/doi.org\/10.1097\/01.mlr.0000160417.39497.a9.","journal-title":"Med Care"},{"key":"1142_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.thromres.2005.06.015","volume":"118","author":"T Arnason","year":"2006","unstructured":"Arnason T, Wells PS, van Walraven C, Forster AJ. Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res. 2006;118:253\u201362. https:\/\/doi.org\/10.1016\/j.thromres.2005.06.015.","journal-title":"Thromb Res"},{"key":"1142_CR22","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/pds.2109","volume":"20","author":"A Cunningham","year":"2011","unstructured":"Cunningham A, Stein CM, Chung CP, et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20:560\u20136. https:\/\/doi.org\/10.1002\/pds.2109.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"1142_CR23","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1055\/a-1508-8187","volume":"122","author":"KJ Lin","year":"2022","unstructured":"Lin KJ, Schneeweiss S, Pawar A, et al. Using a simple prescription gap to determine warfarin discontinuation can lead to substantial misclassification. Thromb Haemost. 2022;122(3):386\u201393. https:\/\/doi.org\/10.1055\/a-1508-8187.","journal-title":"Thromb Haemost"},{"key":"1142_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150\u201361. https:\/\/doi.org\/10.1002\/pst.433.","journal-title":"Pharm Stat"},{"key":"1142_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/096228029300200202","volume":"2","author":"JL Fleiss","year":"1993","unstructured":"Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res. 1993;2:121\u201345. https:\/\/doi.org\/10.1177\/096228029300200202.","journal-title":"Stat Methods Med Res"},{"key":"1142_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cpt.329","volume":"99","author":"SV Wang","year":"2016","unstructured":"Wang SV, Verpillat P, Rassen JA, et al. Transparency and reproducibility of observational cohort studies using large healthcare databases. Clin Pharmacol Ther. 2016;99:325\u201332. https:\/\/doi.org\/10.1002\/cpt.329.","journal-title":"Clin Pharmacol Ther"},{"key":"1142_CR27","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1161\/circulationaha.120.051718","volume":"143","author":"JM Franklin","year":"2021","unstructured":"Franklin JM, Patorno E, Desai RJ, et al. Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE Initiative. Circulation. 2021;143:1002\u201313. https:\/\/doi.org\/10.1161\/circulationaha.120.051718.","journal-title":"Circulation"},{"key":"1142_CR28","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.119.012646","volume":"8","author":"AJ Rose","year":"2019","unstructured":"Rose AJ, Goldberg R, McManus DD, et al. Anticoagulant prescribing for non-valvular atrial fibrillation in the veterans health administration. J Am Heart Assoc. 2019;8: e012646. https:\/\/doi.org\/10.1161\/jaha.119.012646.","journal-title":"J Am Heart Assoc"},{"key":"1142_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4235\/agmr.20.0002","volume":"24","author":"DH Kim","year":"2020","unstructured":"Kim DH. Measuring frailty in health care databases for clinical care and research. Ann Geriatr Med Res. 2020;24:62\u201374. https:\/\/doi.org\/10.4235\/agmr.20.0002.","journal-title":"Ann Geriatr Med Res."},{"key":"1142_CR30","unstructured":"A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05757869. Accessed 17 Jun 2023."},{"key":"1142_CR31","unstructured":"Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05712200. Accessed 17 Jun 2023."},{"key":"1142_CR32","unstructured":"Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants with End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007). Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT05027074. Accessed 29 Nov 2023."},{"key":"1142_CR33","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/s0140-6736(22)00456-1","volume":"399","author":"JP Piccini","year":"2022","unstructured":"Piccini JP, Caso V, Connolly SJ, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 2022;399:1383\u201390. https:\/\/doi.org\/10.1016\/s0140-6736(22)00456-1.","journal-title":"Lancet"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01142-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-024-01142-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01142-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T14:53:57Z","timestamp":1726671237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-024-01142-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1142"],"URL":"https:\/\/doi.org\/10.1007\/s40266-024-01142-9","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"11 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The work reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under award numbers R01AG062713 and K24AG073527, and by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number K23HL151903. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Darae Ko reports consulting fees from Windrose Consulting Group and an investigator-sponsored research grant from Boston Scientific Corporation outside the submitted work. Robert J. Glynn has received research support for unrelated projects through grants to his employer (Brigham and Women\u2019s Hospital) from Amarin, Kowa, Novartis, and Pfizer. Dae Hyun Kim receives grants from the National Institutes of Health for unrelated work, and has received personal fees from Alosa Health and VillageMD. Kueiyu Joshua Lin, Su Been Lee, Zhigang Lu, Susan Cheng, and Sachin J. Shah have no conflicts of interest to declare that may be relevant to the contents of this study","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Medicare data are protected and cannot be shared by study authors, but may be accessed by qualified researchers under a data use agreement with the Centers for Medicare & Medicaid Services (CMS).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The study was approved by the Institutional Review Board at Brigham and Women\u2019s Hospital, Boston, MA, USA.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"A waiver of informed consent was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors have read and approved the final version of the manuscript and agree to be accountable for this work. Concept and design: DHK. Acquisition, analysis, and interpretation of data: DK, KJL, SBL, ZL, SC, SJS, RJG, DHK. Drafting of the manuscript: DK, DHK. Critical review of the manuscript for important intellectual content: DK, KJL, SBL, ZL, SC, SJS, RJG, DHK. Obtained funding: DHK. Administrative, technical, or material support: DHK, SBL. Supervision: DHK.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}